Bradford Navia, Ph.D. M.D | Source | Chief Medical Officer of Aprinoia Therapeutics at APRINOIA Therapeutics

Bradford Navia, Ph.D. M.D, Chief Medical Officer at Aprinoia Therapeutics, a clinical-stage biotech company committed to protecting patients’ brain health and changing outcomes for a broad range of neurodegenerative diseases through best-in-class diagnostic tools and novel therapies. Importantly, he was also actively involved in the design of Eisai early clinical designs for Lecanemab, which was just approved by the FDA.

- His history:
- Associate Professor, Tufts Medical School, Boston
- Executive Director, Sunovion Pharmaceuticals, MA
- Strategic and Clinical Lead, AbbVie, IL
- Senior Director, Eisai, NJ
- Director, Johnson and Johnson, NJ
- Ph.D. in Neuroscience (Genetics), Harvard University
- BA, MD in Columbia University

Extensive clinical development, and regulatory experience in neurology and psychiatry; Parkinson’s Disease, Alzheimer’s Disease, ALS